尿素霜对索拉非尼相关手足皮肤反应的影响:多中心随机双盲对照研究
该多中心随机双盲对照研究纳入288例接受索拉非尼治疗的肝细胞癌患者,比较尿素霜与安慰剂霜预防手足皮肤反应(HFSR)的效果。尿素霜组任何级别HFSR及≥II级HFSR的累积发生率呈降低趋势但无统计学意义;第2周时≥II级HFSR发生率显著低于安慰剂组(13.8% vs 23.9%,P=0.042),第12周HF-QoL评分显著更优(11.8 vs 19.7,P=0.014)。
要点
- 尿素霜组第2周≥II级HFSR发生率显著低于安慰剂组(13.8% vs 23.9%,P=0.042)。
- 尿素霜组第12周HF-QoL评分显著优于安慰剂组(11.8 vs 19.7,P=0.014)。
- 任何级别及≥II级HFSR累积发生率组间差异无统计学意义。
核心结论
- 尿素霜可降低索拉非尼治疗肝细胞癌患者第2周≥II级HFSR发生率,并改善第12周生活质量评分。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照研究,288例接受索拉非尼治疗的肝细胞癌患者纳入分析247例(安慰剂组117例,尿素霜组130例)。
主要发现
- 尿素霜组任何级别HFSR累积发生率呈降低趋势但无统计学意义(log-rank,P=0.247)。
- 尿素霜组≥II级HFSR累积发生率呈降低趋势但无统计学意义(log-rank,P=0.394)。
- 第2周时尿素霜组≥II级HFSR发生率显著低于安慰剂组(13.8% vs 23.9%,P=0.042)。
- 第12周时尿素霜组HF-QoL问卷评分显著优于安慰剂组(11.8 vs 19.7,P=0.014)。
临床怎么用
- 对于接受索拉非尼治疗的肝细胞癌患者,可考虑使用尿素霜以预防或改善HFSR分级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hand-foot skin reaction (HFSR) is the most common adverse event during sorafenib treatment in patients with hepatocellular carcinoma (HCC). In the present study, we aimed to investigate the role of urea cream in the prevention of HFSR or amelioration of HFSR severity. PATIENTS AND METHODS: Patients with HCC were treated with either placebo cream or urea cream for 12 weeks concomitantly with sorafenib treatment. HFSR development, the Hand-Foot Skin Reaction and Quality of Life (HF-QoL) questionnaire score, and adverse events were assessed at 2, 4, 8 and 12 weeks. RESULTS: Of the 288 patients, 247 patients, with 117 patients in the placebo control group and 130 patients in the urea cream group, were analysed. The urea cream group showed a trend towards a lower cumulative incidence of any-grade HFSR (log-rank, P = 0.247) and severe HFSR of grade II or higher (log-rank, P = 0.394) without statistical significance. In the incidence by time point, the incidence of severe HFSR of grade II or higher was significantly lower in the urea cream group than in the placebo control group at 2 weeks (13.8% versus 23.9%, P = 0.042). The urea cream group showed a significantly better HF-QoL questionnaire score than the placebo control group (11.8 versus 19.7, P = 0.014) at 12 weeks. CONCLUSIONS: Treatment with urea cream showed a lower incidence of severe sorafenib-induced HFSR at 2 weeks and reduced the tendency of HFSR development in HCC patients. Therefore, treatment with urea cream may be considered for prophylaxis or improvement of HFSR grade in HCC patients treated with sorafenib. TRIAL REGISTRATION: ClinicalTrials.gov (NCT03212625).
引用
- Lee YS, Jung YK, Kim JH, et al. Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study. Eur J Cancer. 2020. PMID: 33039810. doi:10.1016/j.ejca.2020.09.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。